Thu-Ha Dinh1, Angela Mushavi2, Ray W Shiraishi1, Beth Tippett Barr3, Shirish Balachandra3, Gerald Shambira4, Justice Nyakura4, Sekesai Zinyowera5, Mufuta Tshimanga4, Owen Mugurungi2, Peter H Kilmarx1,3. 1. Center for Global Health, Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. AIDS and TB Department, Ministry of Health and Child Care of Zimbabwe. 3. Center for Global Health, Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention-Zimbabwe. 4. Department of Community Health, University of Zimbabwe. 5. National Microbiology Reference Laboratory, Ministry of Health and Child Care of Zimbabwe, Harare.
Abstract
Background: Preventing mother-to-child transmission of human immunodeficiency virus transmission (MTCT) depends on early initiation of antiretroviral therapy (ART). We report the 18-month MTCT risk during the transition from Option A to Option B+ in Zimbabwe, and assess whether ART preconception could eliminate MTCT in breastfeeding populations. Methods: In 2013, we consecutively recruited a nationally representative sample of 6051 infants aged 4-12 weeks and their mothers from 151 immunization clinics using a multistage stratified cluster sampling method. We identified 1172 human immunodeficiency virus (HIV)-exposed infants and evaluated them at baseline and every 3 months until the child became HIV-infected, died, or reached age 18 months. Results: The cumulative MTCT risk through 18 months postdelivery was 7.0%. Of the HIV-infected mothers, 35.3% started ART preconception, 28.9% during pregnancy, and 9.7% after delivery, and 16.0% received zidovudine during pregnancy. Compared to mothers without antiretroviral drug use, MTCT among those starting ART preconception and during pregnancy was lower by 88% (adjusted hazard ratio [aHR], 0.12; 95% confidence interval [CI], .06-.24) and 75% (aHR, 0.25; 95% CI, .14-.45), respectively. HIV-exposed infants with birth weight <2.5 kg (low birth weight) were 2.6-fold more likely to acquire HIV infection compared to those with birth weight ≥2.5 kg (aHR, 2.57; 95% CI, 1.44-4.59). Controlling for other factors, breastfeeding was not significantly associated with MTCT. Conclusions: ART preconception has the highest impact on reducing MTCT, indicating that HIV-infected, reproductive-age women should be prioritized in "treat-all" strategies. HIV-infected mothers without ART use should be identified at the first immunization visit and treatment initiated to reduce postdelivery MTCT. MTCT risk is higher in mothers with low-birth-weight deliveries. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Preventing mother-to-child transmission of human immunodeficiency virus transmission (MTCT) depends on early initiation of antiretroviral therapy (ART). We report the 18-month MTCT risk during the transition from Option A to Option B+ in Zimbabwe, and assess whether ART preconception could eliminate MTCT in breastfeeding populations. Methods: In 2013, we consecutively recruited a nationally representative sample of 6051 infants aged 4-12 weeks and their mothers from 151 immunization clinics using a multistage stratified cluster sampling method. We identified 1172 human immunodeficiency virus (HIV)-exposed infants and evaluated them at baseline and every 3 months until the child became HIV-infected, died, or reached age 18 months. Results: The cumulative MTCT risk through 18 months postdelivery was 7.0%. Of the HIV-infected mothers, 35.3% started ART preconception, 28.9% during pregnancy, and 9.7% after delivery, and 16.0% received zidovudine during pregnancy. Compared to mothers without antiretroviral drug use, MTCT among those starting ART preconception and during pregnancy was lower by 88% (adjusted hazard ratio [aHR], 0.12; 95% confidence interval [CI], .06-.24) and 75% (aHR, 0.25; 95% CI, .14-.45), respectively. HIV-exposed infants with birth weight <2.5 kg (low birth weight) were 2.6-fold more likely to acquire HIV infection compared to those with birth weight ≥2.5 kg (aHR, 2.57; 95% CI, 1.44-4.59). Controlling for other factors, breastfeeding was not significantly associated with MTCT. Conclusions: ART preconception has the highest impact on reducing MTCT, indicating that HIV-infected, reproductive-age women should be prioritized in "treat-all" strategies. HIV-infected mothers without ART use should be identified at the first immunization visit and treatment initiated to reduce postdelivery MTCT. MTCT risk is higher in mothers with low-birth-weight deliveries. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
ART initiation; Zimbabwe; birth weight; mother-to-child HIV transmission
Authors: Risa M Hoffman; Vivian Black; Karl Technau; Karin Joan van der Merwe; Judith Currier; Ashraf Coovadia; Matthew Chersich Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha Journal: N Engl J Med Date: 2008-06-04 Impact factor: 91.245
Authors: I Grosch-Woerner; K Puch; R F Maier; T Niehues; G Notheis; D Patel; S Casteleyn; C Feiterna-Sperling; S Groeger; D Zaknun Journal: HIV Med Date: 2008-01 Impact factor: 3.180
Authors: Anne Esther Njom Nlend; Annie Nga Motazé; Suzie Moyo Tetang; Cécile Zeudja; Marcus Ngantcha; Mathurin Tejiokem Journal: PLoS One Date: 2016-03-21 Impact factor: 3.240
Authors: Silvia Arboleya; Borja Sánchez; Gonzalo Solís; Nuria Fernández; Marta Suárez; Ana M Hernández-Barranco; Christian Milani; Abelardo Margolles; Clara G de Los Reyes-Gavilán; Marco Ventura; Miguel Gueimonde Journal: Int J Mol Sci Date: 2016-04-29 Impact factor: 5.923
Authors: Beth A Tippett Barr; Monique van Lettow; Joep J van Oosterhout; Megan Landes; Ray W Shiraishi; Ermias Amene; Erik Schouten; Nellie Wadonda-Kabondo; Sundeep Gupta; Andrew F Auld; Thokozani Kalua; Andreas Jahn Journal: Lancet HIV Date: 2018-11-19 Impact factor: 12.767
Authors: H J Zar; D P Moore; S Andronikou; A C Argent; T Avenant; C Cohen; R J Green; G Itzikowitz; P Jeena; R Masekela; M P Nicol; A Pillay; G Reubenson; S A Madhi Journal: Afr J Thorac Crit Care Med Date: 2020-10-13
Authors: Nadia M Ikumi; Thokozile R Malaba; Komala Pillay; Marta C Cohen; Hlengiwe P Madlala; Mushi Matjila; Dilly Anumba; Landon Myer; Marie-Louise Newell; Clive M Gray Journal: AIDS Date: 2021-04-01 Impact factor: 4.177
Authors: Phillip P Salvatore; Gatien de Broucker; Lara Vojnov; William J Moss; David W Dowdy; Catherine G Sutcliffe Journal: AIDS Date: 2021-02-02 Impact factor: 4.632
Authors: Nicole C McCann; Jennifer Cohn; Clare Flanagan; Emma Sacks; Sushant Mukherjee; Rochelle P Walensky; Oluwarantimi Adetunji; Kenneth K Maeka; Christopher Panella; Addmore Chadambuka; Haurovi Mafaune; Collins Odhiambo; Kenneth A Freedberg; Andrea L Ciaranello Journal: J Acquir Immune Defic Syndr Date: 2020-07-01 Impact factor: 3.771